tbuckley/cabot-search huggingface dataset:
Sexual Violence Associated With Sexual Identity and Gender Among California Adults Reporting Their Experiences as Adolescents and Young Adults
Authors: David J. Inwards-Breland, Nicole E. Johns, Anita Raj
Journal: JAMA Network Open (2022)

Disproportionate levels of violence exist in lesbian, gay, bisexual, queer, asexual, and other sexual identity (LGBQA+) communities, often starting in adolescence and young adulthood, but little research exists on the range of sexual violence (SV) experiences.To assess risk of experiences of sexual violence among California LGBQA+ adults during adolescence and young adulthood.This survey study analyzed data from Cal-VEX 2020, a state-representative survey of California residents aged 18 years and older, to assess associations between LGBQA+ identification and types of SV experienced in adolescence (ages 13-17 years) and young adulthood (ages 18-24 years) using gender-stratified adjusted logistic regression. Forms of SV included verbal, cyber, and coercion or physically aggressive sexual harassment; homophobic or transphobic slurs; and forced sex.Sexual identity.The outcome of interest was experiences with any 5 forms of sexual violence (verbal sexual harassment, homophobic or transphobic slurs, cyber sexual harassment, sexual coercion or physically aggressive sexual harassment, and forced sex) during adolescence or young adulthood.A total of 2102 contacted individuals (response rate, 26.2%) completed the Cal-VEX survey and were included in these analyses. Among these, the mean (SD) age was 46.6 (17.7) years, 1149 identified as female, 953 identified as male, and 214 respondents (9.6%) identified as LGBQA+. Compared with heterosexual individuals, LGBQA+ individuals had significantly higher odds of having experienced homophobic or transphobic slurs (women: AOR, 14.65; 95% CI, 5.14-41.77; men: AOR, 14.17; 95% CI, 6.96-28.86) and forced sex (women: AOR, 5.35; 95% CI, 2.74-10.43; men: AOR, 2.68; 95% CI, 1.01-7.10) in adolescence. LGBQA+ women also had higher odds of having experienced verbal and coercion or physically aggressive sexual harassment in adolescence (AOR, 2.33; 95% CI, 1.30-4.19). In young adulthood, LGBQA+ individuals also had higher odds of having experienced homophobic or transphobic slurs (women: AOR, 18.58; 95% CI, 7.12-48.49; men: AOR, 16.73; 95% CI, 8.26-33.92) in young adulthood. LGBQA+ men also had higher odds of having experienced homophobic or transphobic slurs (AOR, 16.73; 95% CI, 8.26-33.92); verbal (AOR, 3.29; 95% CI, 1.44-7.53), cyber (AOR, 6.32; 95% CI, 1.50-26.52), and coercion or physically aggressive (AOR, 5.54; 95% CI, 2.08-14) sexual harassment; and forced sex (AOR, 21.26; 95% CI, 5.63-80.35) in young adulthood.This survey study found that adult LGBQA+ individuals were at increased risk for having experienced SV across the continuum during adolescence and young adulthood, consistent with prior research. Multifold solutions are needed to support LGBQA+ youth, including altering social norms accepting SV and homophobia, creating safer schools and other institutional environments, and supporting healthy sexual and romantic partnerships.
The temperature of atherosclerotic plaques is correlated with matrix metalloproteinases concentration in patients with acute coronary syndromes Konstantinos Toutouzas, Christodoulos Stefanadis, Eleftherios Tsiamis, Manolis Vavuranakis, Costas Tsioufis, Dorotheallll Tsekoura, Sofia Vaina, Pavlos Toutouzas. Hippokration Hospital, Athens, Greece
Journal: Journal of the American College of Cardiology (2001)
A phase II study of niraparib and dostarlimab with radiation in patients with metastatic pancreatic cancer.
Authors: Aparna Raj Parikh, Colin D. Weekes, Lawrence Scott Blaszkowsky, Joseph Wang Franses, David Tsai Ting, Arnav Mehta, Eric Roeland, David P. Ryan, Jill N. Allen, Jeffrey William Clark, Leilana Ly, Isabella Loosbrock, Joy X. Jarnagin, Allison Bannon, Darcy K. Caldwell, Beow Y. Yeap, Jennifer Y. Wo, Theodore S. Hong
Journal: Journal of Clinical Oncology (2022)

564 Background: PARP inhibitors have activity as monotherapy in BRCA1/2 mutated metastatic pancreatic cancer; however, several other genes and associated proteins exist in the homologous recombination repair (HRR) pathway promoting resistance to chemotherapy and radiation-induced damage. Tumors with HRR deficiency have an impaired ability to repair themselves and are susceptible to PARP inhibition, but ionizing radiation can also induce DNA breaks. Ongoing research suggests that PARP inhibitors may cause radio-sensitization and may also enhance sensitivity to immunotherapy. We conducted a phase 2 study of niraparib and dostarlimab with radiation in a biomarker unselected PDAC population given PARP inhibitors' immunomodulatory and radiosensitizing effects. Methods: In this open-label, single-arm, phase-2 study, eligible patients had histologically confirmed MSS PDAC, ECOG PS 0-1, and progressed on at least one line of jm. Treatment consisted of niraparib 200 mg daily on a 21-day cycle, dostarlimab 500 mg every 3 weeks every 4 weeks for the first four doses, then 1000 mg every 6 weeks, and 3 fractions of 8 Gy at Cycle 2. Treatment continued until progressive disease, discontinuation, or withdrawal. The primary endpoint was DCR by RECIST 1.1 with radiological evaluations every 3 months. Secondary endpoints included DCR by irRECIST, PFS, OS, and safety. Responses were defined as disease control outside the radiation field. We obtained serial tumor biopsies, including pre-treatment. A two-stage design was used, requiring disease control in at least one of the first 15 patients before proceeding to the full accrual of 25 patients. Intention to treat analysis included all patients receiving at least one dose of any study agent. Results: We enrolled and treated 15 pts (median age 60 years [range 37-77], 53% male) from 08/2020 to 05/2021. Overall, DCR was 0/15 (95% CI: 0-22%), median PFS was 1.6 months (95% CI: 1.1-2.7), and median OS 3.1 months (95% CI: 1.5-7.7). Among 27 treatment-related serious adverse events, 15 (56%) were grade 3, including decreased CD4 lymphocytes, thrombocytopenia, anemia, and fatigue being the most common. Conclusions: The combination of niraparib and dostarlimab with radiation did not meet the pre-specified criteria for expansion to full accrual. Further analyses of dose intensity in this heavily pretreated and evaluation of in-field responses are underway. Further investigation of the combination with biomarker selection is warranted. Clinical trial information: NCT04409002.
Hyperemic coronary blood flow induced by selective adenosine A2A receptor stimulation: First report in patients of a well tolerated novel agent for stress imaging Morton J. Kern, John M. Hodgson, James D. Rossen, Tim A. Fischell, Richard J. Barrett, Saad R. Bitar, Michael D. Eisenhauer. St. Louis University, St. Louis, MO, MetroHealth Medical Center, Cleveland, OH
Journal: Journal of the American College of Cardiology (2001)
Medical News.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
British Society of Gastroenterology
Authors: D Rew, M Kellett, S Potten, S Roberts, A Muller, K Stainer, L Fullwood, M Hawkins, A Cowley, M Petroni, R Jazrawi, A Grundy, A Lanzini, M Pigozzi, A Biasio, W Heaton, J Virjee, T Northfield, D Williams, G Thompson, M Marples, V Mani, C Bate, T O'hanrahan, J Bancewicz, R Playford, T Freeman, C Quinn, J Calam, J Ibbotson, J Lowes, H Chahal, H Gaston, S Kumararatne, R Allan
Journal: Gut (1990)

University Hospital, Nottingham) The mani- festations of chronic mesenteric ischaemia are often protean, but it has been claimed that Doppler ultrasound analysis of the abdominal vasculature may discriminate between proximal stenotic arteries and be a useful non- invasive screening tool before angiography.Six patients aged (mean (SEM)) 63 (3) years were referred for Doppler scanning.All described postprandial abdominal pain in the presence of a normal endoscopy.Two gave a history of weight loss and all had evidence of vascular disease.The following Doppler parameters of superior mesenteric (SMA) and coeliac arteries (CA) were examined preprandially following an overnight fast and for one hour after an 800 kcal meal: peak systolic (Vmax) and end diastolic (Vmin) velocities, pulsatility index (PI) and velocity of flow (V).Peak changes were accepted.Twenty volunteers (20 SMA's and 10 coeliac arteries) aged 20-65 years were similarly examined to establish normal values.The inferior mesenteric artery was inconsistently insonated.Mean (SEM) coefficients of variance for parameters studied were all less than 10%.Food in the control group increased SMA Vmax from 100-5 (4-2) cm/s to 154 (7-8) cm/s, Vmin (16 (0-9) cm/s to 46 (2-5) cm/s), V (35 (I 1) cm/s to 59 2 (5 2) cm/s) whilst PI fell from 3-6 (0-2) units to 1-8 (0-1) units.For CA the changes were: Vmax (120 (7) cm/s to 130 (22) cm/s), Vmin (30 (3 3) cm/s to 40 (4-8) cm/s), V (30 (3 3) cm/s to 41 (3 3) cm/s), and PI (1 5 (0 2) to 1-5 (0-1) units).All patients had normal fasting SMA and CA parameters.Postprandially, one patient's SMA Vmax/Vmin fell from 96/14 cm/s to 63/12 cm/s and V from 25 to 22 cm/s (heart failure).One patient increased SMA Vmax/Vmin significantly over controls from 108/20 cm/s to 312/78 cm/s with V from 28 to 70 cm/s.A third patient had CA Vmax/Vmin from 127/36 cm/s to 225/70 cm/s.These changes may represent non-occlusive and occlusive mesenteric ischaemia.When vascular ischaemia is suspected, Doppler ultrasound may be a useful screening test.Symptomatic patients should be scanned pre and post prandially.
Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease. A multicenter randomized trial. Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators
Journal: JAMA (1997)

To compare clinical and functional status in patients who had similar 5-year survival after coronary artery bypass grafting (CABG) and percutaneous transluminal coronary angioplasty (PTCA).Randomized trial of 1829 patients followed for an average 5.4 years.Patients with multivessel coronary artery disease suitable for both CABG and PTCA and not previously revascularized.Coronary artery bypass grafting or PTCA within 2 weeks after randomization.Symptoms, exercise test results, medication use, and quality-of-life measures collected at 4 to 14 weeks, and at 1, 3, and 5 years after randomization.Intention to treat.Differences in angina-free rates between patients assigned to PTCA and CABG decreased from 73% vs 95% at 4 to 14 weeks (P<.001) to 79% vs 85% at 5 years (P=.007). Similar patterns were observed for exercise-induced angina and ischemia, except 5-year differences were not significant. At follow-up of 1 year and later, quality of life, return to work, modification of smoking and exercise behaviors, and cholesterol levels were similar for the 2 treatments. Compared with patients assigned to CABG, use of anti-ischemic medication was higher in patients assigned to PTCA, while smaller differences were observed for other medications. Among patients angina-free at 5 years, 52% of patients who had PTCA required revascularization after the initial procedure vs 6% of patients who had CABG.The narrowing of treatment differences in angina and exercise-induced ischemia rates can be attributed to a return of symptoms among patients assigned to CABG and incremental surgical procedures among patients assigned to PTCA. Patients assigned to PTCA apparently were able to tolerate higher rates of residual ischemia as evidenced by comparable quality of life and 5-year survival.
Educational Council for Foreign Medical Graduates
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes
Authors: Juraj Koska, Hertzel C. Gerstein, Paul J. Beisswenger, Peter D. Reaven
Journal: Diabetes Care (2022)

OBJECTIVE To evaluate the association of a multicomponent advanced glycation end product (AGE) panel with decline in kidney function and its utility in predicting renal function loss (RFL) when added to routine clinical measures in type 2 diabetes. RESEARCH DESIGN AND METHODS Carboxymethyl and carboxyethyl lysine and methylglyoxal, 3-deoxyglucosone, and glyoxal hydroimidazolones were measured in baseline serum and plasma samples, respectively, from Action to Control Cardiovascular Risk in Diabetes (ACCORD) (n = 1,150) and Veterans Affairs Diabetes Trial (VADT) (n = 447) participants. A composite AGE score was calculated from individual AGE z scores. The primary outcome was a sustained 30% decline in estimated glomerular filtration rate (eGFR) (30% RFL in both cohorts). Secondary outcomes (in ACCORD) were 40% RFL, macroalbuminuria, and high-risk chronic kidney disease (hrCKD). RESULTS After adjustment for baseline and follow-up HbA1c and other risk factors in ACCORD, the AGE score was associated with reduction in eGFR (β-estimate −0.66 mL/min ⋅ 1.73 m2 per year; P = 0.001), 30% RFL (hazard ratio 1.42 [95% CI 1.13–1.78]; P = 0.003), 40% RFL (1.40 [1.13–1.74]; P = 0.003), macroalbuminuria (1.53 [1.13–2.06]; P = 0.006), and hrCKD (1.88 [1.37–2.57]; P &amp;lt; 0.0001). AGE score improved net reclassification (NRI) and relative integrated discrimination (IDI) for 30% RFL (NRI 23%; P = 0.02) (relative IDI 7%; P = 0.009). In VADT, the AGE score calculated by the ACCORD-derived coefficients was associated with 30% RFL (1.37 [1.03–1.82); P = 0.03) and improved NRI (24%; P = 0.03) but not IDI (P = 0.18). CONCLUSIONS These data provide further support for a causal role of AGEs in diabetic nephropathy independently of glycemic control and suggest utility of the composite AGE panel in predicting long-term decline in renal function.
Advances in Lymphedema
Authors: Stanley G. Rockson
Journal: Circulation Research (2021)

Lymphedema is a common, complex, and inexplicably underappreciated human disease. Despite a history of relative neglect by health care providers and by governmental health care agencies, the last decade has seen an explosive growth of insights into, and approaches to, the problem of human lymphedema. The current review highlights the significant advances that have occurred in the investigative and clinical approaches to lymphedema, particularly over the last decade. This review summarizes the progress that has been attained in the realms of genetics, lymphatic imaging, and lymphatic surgery. Newer molecular insights are explored, along with their relationship to future molecular therapeutics. Growing insights into the relationships among lymphedema, obesity, and other comorbidities are important to consider in current and future responses to patients with lymphedema.
Dogs bites
Authors: L. Booker
Journal: JAMA (1985)

<h3>To the Editor.—</h3> The article by Karlson<sup>1</sup>did not purport to be more than an incidence report, and I fully agree with her statement that "more investigative research must be done." This article initially emphasized that facial trauma secondary to dog bites is severe, but later acknowledged that the survey reflected "the minimum estimates of the incidence of facial injuries from dog bites," because untreated and nonhospital-treated victims were not included. Perhaps the author could be less dogmatic (pun intended) and appreciate that a relatively small percentage of dog bites inflict "severe" facial injury. Parrish et al<sup>2</sup>reported that only 4% of dog bites involving the head, face, and neck were "severe," while 73% were considered "minor." Callaham<sup>3</sup>observed that facial wounds from dog bites were associated with only a 4% infection rate, while hand wounds had a 28% rate. Clearly, facial trauma is a matter of concern,
Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma
Authors: Gilles Salles, Martin J.S. Dyer, Daniel James Hodson, Krimo Bouabdallah, Loic Ysebaert, Guillaume Cartron, Andrew John Davies, Alexey V Danilov, Christopher Fegan, Ebenezer A Kio, Xi Huang, Siddhartha Mitra, Simon Rule, Franck Morschhauser
Journal: Blood (2018)
Error in Author Byline
Authors: Kevin Alexander, Sharmila Dorbala
Journal: JAMA Cardiology (2021)

Mohammed Majid Akhtar, MD; Massimiliano Lorenzini, MD; Menelaos Pavlou, PhD; Juan Pablo Ochoa, MD; Constantinos O’Mahony, MD; Maria Alejandra Restrepo-Cordoba, MD; Diego Segura-Rodriguez, MD; Francisco Bermúdez-Jiménez, PhD; Pilar Molina, MD, PhD; Sofia Cuenca, MD, PhD; Flavie Ader, PharmD; Jose M. Larrañaga-Moreira, MD; Maria Sabater-Molina, PhD; Maria I. Garcia-Alvarez, MD; Larraitz Gaztañaga Arantzamendi, PhD; Grazyna Truszkowska, MSc; Martin Ortiz-Genga, MD; Itziar Solla Ruiz, MD; Søren Kristian Nielsen, MD; Torsten Bloch Rasmussen, MD, PhD; Ainhoa Robles Mezcua, MD; Jorge Alvarez-Rubio, MD; Hans Eiskjaer, DMSc; Mathias Gautel, MD; José M. Garcia-Pinilla, MD, PhD; Tomas Ripoll-Vera, MD, PhD; Jens Mogensen, MD, PhD; Javier Limeres Freire, MD; Jose F. Rodríguez-Palomares, MD; Maria Luisa Peña-Peña, MD; Diego Rangel-Sousa, MD; Julian Palomino-Doza, PhD; Xabier Arana Achaga, MD; Zofia Bilinska, MD, PhD; Estibaliz Zamarreño Golvano, MD; Vincent Climent, MD, PhD; Marina Navarro Peñalver, MD; Roberto Barriales-Villa, MD; Philippe Charron, MD, PhD; Raquel Yotti, MD; Esther Zorio, MD, PhD; Juan Jiménez-Jáimez, PhD; Pablo Garcia-Pavia, MD, PhD; Perry M. Elliott, MD; European Genetic Cardiomyopathies Initiative Investigators
Pathology
Authors: Robert W. McDivitt
Journal: JAMA (1977)

In this seventh edition of Anderson's<i>Pathology</i>, which updates the previous edition published in 1971, John M. Kissane joins W. A. D. Anderson as coauthor. The text contains approximately 300 more pages than the previous one. Of the 55 contributors, 22 are new to this edition, while the general format remains similar. The first 18 chapters (736 pages) concern general pathology; the remainder follow the organ system format. Several new chapters, including one on geographic pathology have been added. The individual chapters are generally of high quality, though somewhat uneven. Most authors whose chapters appeared in previous editions have extensively revised their text and added new illustrations; however, a few chapters show little change. Overall, illustrations remain of high quality. A bibliography appended to each chapter serves as a useful guide to pertinent current literature. This edition has been designed to include topics pertinent to the preclinical curriculum, emphasizing clinico-pathological
An Address Delivered at the Opening of the Section of Medicine
Authors: T. G. Stewart
Journal: BMJ (1878)

WRg.2-.my.case, he also had been equally, happy hihiit iht -deaig:it<n ulnar nferve.Thus, gentlemen, aiming discursively at/ murh and accomplishing only, I fear, too little, I have wanderedt ;over the field of more recent surgical advancement, and it only.nowr.remains for me -
Abstract 17224: Volatile Anesthetic Agents Increase Cerebral to Systemic Blood Flow Ratio in Children Undergoing Cardiac Magnetic Resonance Imaging
Authors: Amulya Buddhavarapu, Luisa Raga, Euleche Alanmanou, Prashob Porayette
Journal: Circulation (2018)

Introduction: Cardiac magnetic resonance imaging (CMR) can reliably assess hemodynamics in children. Anesthetic agents may affect cerebral blood flow (CBF) and change the cerebral to systemic perfusion ratio. Hypothesis: Volatile anesthetic agents cause significant cerebral vasodilation resulting in descending aorta (DAo) flow reversal. Methods: Blood flow was measured in patients who underwent cine phase contract velocity mapping during CMR (1.5T, Philips Ingenia, Amsterdam, The Netherlands) with or without general anesthesia (GA) at our institution. Patients with a known cause for flow reversal in DAo (e.g. aortic insufficiency, aorto-pulmonary shunt/collaterals) or brain pathology were excluded. Flows in superior vena cava (SVC, surrogate for CBF), ascending aorta (AAo, measure of cardiac output), and DAo (measure of lower body perfusion) were analyzed. Measures of central tendency, standard deviation, correlation coefficient and Student’s t-test were calculated. Variables including anesthetic agents, body surface area (BSA), mechanical ventilator parameters and vital signs were assessed. Results: A total of 93 CMR scans were performed with GA (n=43, age 3 m to 15 y, BSA 0.29-2.4 m 2 ) or without GA (n=50, 2 w to 21 y, BSA 0.2-2.89 m 2 ). There was significant flow reversal in DAo (mean 7.62% +/- SD 7%) in GA group using volatile agents compared to non-GA patients (1.16% +/- 1.78%; p-value &lt;0.001). SVC flow was higher in GA (1.66+/-1.02 ml/min/m 2 ) than non-GA patients (1.28+/-0.53 ml/min/m 2 ) but did not reach statistical significance (p=0.06). GA group had significantly higher SVC (cerebral blood) to AAo flow (cardiac output) ratio (0.53 +/- 0.13) than non-GA group (0.44 +/- 0.17; p=0.003), probably from increased CBF from cerebral vasodilation by volatile anesthetic agents. Patients with BSA &gt;1.2 m 2 and GA (0.84 +/- 0.27) had a tendency to have higher SVC/DAo flow ratio compared to non-GA (0.69 +/- 0.3; p = 0.06) patients. There was a positive correlation between the end tidal CO 2 and SVC flow (r 0.486, R 2 0.236). Conclusions: The flow rates of SVC, AAo and DAo using CMR must be interpreted with caution in children, taking into account the effects of GA on the cerebral and lower body perfusion. This difference may be relevant in patients with congenital heart disease, especially with cavo-pulmonary and Fontan circulation.